Navigation Links
Premier Micronutrient Launches Supplement for Hearing Health
Date:10/9/2007

PMC Partners with the EAR Foundation to Introduce a Nutritional Product to

Address Hearing Loss, Protect against Hearing Impairment

NASHVILLE, Tenn., Oct. 9 /PRNewswire/ -- Premier Micronutrient Corporation (PMC) announces the launch of a Hearing Health micronutrient supplement designed to reduce tinnitus (ringing in the ear) and provide cellular protection against hearing impairment and balance disorders. Previously available only to scientific study participants and members of the U.S. military, the Hearing Health formulation is now available to a general consumer audience through hearing health professionals and the PMC website at http://www.mypmcinside.com.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071009/CLTU090 )

According to the National Institutes of Health (NIH), approximately 28 million Americans have some level of hearing impairment due to the combined effects of noise, aging, disease and heredity, making hearing damage a societal problem. Approximately ten percent of Americans ages 22-60 already may have suffered permanent damage to their hearing from excessive noise exposure; millions more are at risk due to the growing popularity of activities such as NASCAR races and repeated exposure to loud music and industrial noise.

The formulation was evaluated in collaboration with the Naval Medical Center in San Diego, Calif., where U.S. Marine personnel with balance disorders from blast-related head injuries sustained in Iraq are treated in the Center's Spatial Orientation Center. The study included several measuring techniques for hearing and balance performance, including sensory organization, dynamic gait index and balance confidence. Clinical findings indicate that patients receiving the PMC formulation in addition to standard therapy performed better on all measures than those
'/>"/>

SOURCE Premier Micronutrient Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
2. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
3. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
4. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
5. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
6. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
7. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
8. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
9. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
10. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
11. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2008)...s innovation leadership and long-term commitment t...Nov. 24 Schering-Plough ...al update on boceprevir, its lead investigational ...hase III development. The company believes bocepr...best-in-class protease inhibitor for treating chro...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
(Date:11/24/2008)...Nov. 24 GeneThera, Inc.,...gin offering its Real Time,PCR test for Johne,s d..., GeneThera is set to begin offering its Jo...of 2009. According to GeneThera Chairman, Dr. Ton... real time PCR test for Johne,s disease,called H...
(Date:11/24/2008).... 24 Medarex, Inc. (Nas...hase 1b clinical trial for MDX-1106 (ONO-4538: dev...fully human anti-PD-1 antibody for the treatment o... pathway may play an important role in tumor evasi...lso promote the persistence of certain chronic vir...
Breaking Medicine Technology:Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 2Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 3Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer 4Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 1Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 2Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey 1237 3New class of drug offers hope to treatment resistant AIDS patients 777 1New class of drug offers hope to treatment resistant AIDS patients 777 2New class of drug offers hope to treatment resistant AIDS patients 777 3Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 1Dendreon Secures 24130 Million Committed Equity Financing Facility 1236 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 1Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 2Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis 1234 3
... HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGeni...n, Chief Scientific Officer will,present an update...using the Company,s proprietary synDNA(TM) technol... in Malaga, Spain between May 23,and May 25., Dr. ...ts of,synDNA(TM) based vaccines in mice, rabbits a...
... EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - N...ed today results of its,pivotal Phase III trauma t...oxygen-carrying red blood cell substitute. The,tri...he treatment,of life-threatening red blood cell lo...s are not available, not for use,interchangeably w...
Other Medicine Technology:CytoGenix to Present at 2007 International DNA Vaccines Conference,in Spain 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 2Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 3Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 4Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 5Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 6Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 7Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study 8
(Date:12/1/2008)...alysis of the National Cancer Institute,s cancer r...r women experience delayed or incomplete radiation...d that this suboptimal care can lead to worse outc... Medical College and colleagues found that among a...breast cancer registry patients aged 65 and older,...
(Date:12/1/2008)...D, Mass., Dec. 1 MassMutual Retire...ts to support its increasing nonprofit business. N...mpared to last year. , , Dan Darby joined ...alist for the Western region. He reports to M. Pal... market, for MassMutual,s Retirement Services Divi...
(Date:12/1/2008)...f., Dec. 1 Senetek PLC,...ny engaged in the,development of technologies tha...today that Dynamics Group AG, specialists in the f...agement and research with offices in Zurich,Bern... Company. , The Research Report, available ...
(Date:12/1/2008)...ing, steroids effective against plantar fasciitis...HealthDay News) -- Italian researchers say they,ve...nt for the painful foot condition known as plantar...ing" and steroid injections guided by ultrasound, ...ercent success rate in tackling a condition that a...
Breaking Medicine News(10 mins):Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3
...man holds the hand of a little boy, looking at a r...e area, which was in wreck two years ago, washed a...am village is exuding life now. Along the innocent...h of Chennai, India, new casurina saplings are kne...
...round the corner and this is the time to make new ...7 ?// Health watchers suggest- give yourself ...and food intake the whole year-round. Limiting...very important step, if you want to keep your hear...
...t Mayo Clinic have successfully isolated nanoparti...d have isolated proteins, RNA and DNA that appear ..., which appear in the December issue of the Journa...ficant because it is one step closer in solving th...
...Research Service (ARS) scientists have reported th...s of wheat have been found to produce flour with 2...ard J. Souza, research leader of the ARS Soft Whea...io and colleagues Mary J. Guitteri and Karen M. Pe...
Other Medicine News:Health News:Tsunami-Hit Coastal Regions Needs More Relief 2Health News:Gift Yourself A Healthy Heart 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3
Creatinine Test Kit (enzymatic), Wavelength: 340 nm. Linear range: up to 20 mg/dL.
Kinetic and endpoint methods for the quantitative determination of creatinine in serum.
For the quantitative determination of creatinine in serum. Fixed Time Reaction measured at 540 nm. Linearity: 25 mg/dl. Express Kit with Ready-to-Use Liquid.
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C.
Medicine Products: